Table 1.
In vitro interaction of PPIs with FLC against resistant C. albicans.
| PPIsa | Strainsb | MIC80 (µg/mL)c | FICI model | ΔE model | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alone | Combined | FICIc | INa | ΣSYN (%)c | ΣANT (%)c | INa | ||||
| PPIs | FLC | PPIs | FLC | |||||||
| OME | CA10 | >512 | >512 | 32 | 0.5 | 0.06 | SYN | 1469.95 | −5.31 | SYN |
| CA16 | >512 | >512 | 32 | 0.5 | 0.06 | SYN | 1663.1 | −18.05 | SYN | |
| CA103 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1196.35 | −9.63 | SYN | |
| CA137 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1089.68 | −9.77 | SYN | |
| CA632 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1100.53 | −3.94 | SYN | |
| CA20003 | >512 | >512 | 32 | 0.5 | 0.06 | SYN | 1101.23 | −3.92 | SYN | |
| LAN | CA10 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1244.77 | −0.61 | SYN |
| CA16 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1437.05 | −66.34 | SYN | |
| CA103 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1079.33 | −15.94 | SYN | |
| CA137 | >512 | >512 | 16 | 1 | 0.03 | SYN | 816.71 | −7.27 | SYN | |
| CA632 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1249.21 | −60.38 | SYN | |
| CA20003 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1103.44 | −44.94 | SYN | |
| PTP | CA10 | >512 | >512 | 64 | 1 | 0.13 | SYN | 1341.94 | −8.84 | SYN |
| CA16 | >512 | >512 | 64 | 1 | 0.13 | SYN | 1653.07 | −24.73 | SYN | |
| CA103 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1106.52 | −95.84 | SYN | |
| CA137 | >512 | >512 | 32 | 1 | 0.06 | SYN | 823.01 | −64.51 | SYN | |
| CA632 | >512 | >512 | 64 | 1 | 0.13 | SYN | 1177.14 | −63.02 | SYN | |
| CA20003 | >512 | >512 | 64 | 1 | 0.13 | SYN | 1057.08 | −53.32 | SYN | |
| RAB | CA10 | 256 | >512 | 16 | 1 | 0.06 | SYN | 1149.42 | −27.13 | SYN |
| CA16 | 256 | >512 | 16 | 1 | 0.06 | SYN | 1157.63 | −9.11 | SYN | |
| CA103 | 256 | >512 | 32 | 2 | 0.13 | SYN | 1044.78 | −79.34 | SYN | |
| CA137 | 256 | >512 | 16 | 2 | 0.07 | SYN | 876.45 | −74.15 | SYN | |
| CA632 | 512 | >512 | 16 | 4 | 0.04 | SYN | 1168.12 | −163.45 | SYN | |
| CA20003 | 128 | >512 | 32 | 2 | 0.25 | SYN | 1235.58 | −130.41 | SYN | |
| ESO | CA10 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1334.34 | −18.4 | SYN |
| CA16 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1316.71 | −1.07 | SYN | |
| CA103 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1178.25 | −83.86 | SYN | |
| CA137 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1146.03 | −49.13 | SYN | |
| CA632 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1062.42 | −18.3 | SYN | |
| CA20003 | >512 | >512 | 32 | 1 | 0.06 | SYN | 1086.97 | −26.40 | SYN | |
| ILA | CA10 | >256 | >512 | 8 | 1 | 0.03 | SYN | 1072.23 | −5.44 | SYN |
| CA16 | >256 | >512 | 8 | 1 | 0.03 | SYN | 1201.75 | −10.62 | SYN | |
| CA103 | >256 | >512 | 16 | 1 | 0.06 | SYN | 944.53 | −95.54 | SYN | |
| CA137 | >256 | >512 | 8 | 1 | 0.03 | SYN | 1045.04 | −7.57 | SYN | |
| CA632 | >256 | >512 | 8 | 2 | 0.04 | SYN | 953.47 | −151.16 | SYN | |
| CA20003 | >256 | >512 | 8 | 1 | 0.03 | SYN | 1306.81 | −47.30 | SYN | |
aPPIs: Proton pump inhibitors; IN, interpretation; SYN, Synergism; OME, omeprazole; LAN, Lansprazole; PTP, Pantoprazole; RAB, Rabeprazole; ESO, Esomeprazole; ILA, Ilaprazole;
bCA, Candida albicans;
cThe MIC80 MIC was defined as the lowest concentration showing 80% growth inhibition; FICI, fractional inhibitory concentration index; ΣSYN and ΣANT were the sums of the percentages of all statistically significant synergistic and antagonistic interactions; MIC80 values, FICIs, ΣSYN and ΣANT are the median of three independent experiments.